V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, Sri Banerjee, B. Monk, K. Ushijima, R. Penson, R. Kristeleit, M. Fabbro, M. Orlando, H. Mackay, M. Ren, R. Orlowski, L. Dutta, D. Lorusso
{"title":"lenvatinib + pembrolizumab治疗晚期子宫内膜癌(aec)的随机3期研究:DNA错配修复缺陷(DMMR)肿瘤患者的亚组分析","authors":"V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, Sri Banerjee, B. Monk, K. Ushijima, R. Penson, R. Kristeleit, M. Fabbro, M. Orlando, H. Mackay, M. Ren, R. Orlowski, L. Dutta, D. Lorusso","doi":"10.1136/ijgc-2021-igcs.2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19692,"journal":{"name":"Oral abstracts","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors\",\"authors\":\"V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, Sri Banerjee, B. Monk, K. Ushijima, R. Penson, R. Kristeleit, M. Fabbro, M. Orlando, H. Mackay, M. Ren, R. Orlowski, L. Dutta, D. Lorusso\",\"doi\":\"10.1136/ijgc-2021-igcs.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19692,\"journal\":{\"name\":\"Oral abstracts\",\"volume\":\"12 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2021-igcs.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-igcs.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors